Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
Tom MartinSaad Z UsmaniJordan M SchecterTito RocciaCarolyn C JacksonWilliam DeraedtTzu-Min YehArnob BanerjeeLida PacaudAshraf GarrettMeaghan BartlettAnja HaltnerSuzy Van SandenJoris DielsSatish ValluriImtiaz A SamjooPublished in: Current medical research and opinion (2022)
These analyses demonstrate improved efficacy with cilta-cel versus ide-cel for all outcomes over longer follow-up and highlight its therapeutic potential in triple-class exposed RRMM patients.